Home » Stocks » CRMD

CorMedix, Inc. (CRMD)

Stock Price: $7.62 USD -1.40 (-15.52%)
Updated Mar 2, 2021 4:00 PM EST - Market closed
After-hours: $7.65 +0.03 (0.39%) Mar 2, 4:01 PM
Market Cap 289.84M
Revenue (ttm) 208,295
Net Income (ttm) -21.24M
Shares Out 29.60M
EPS (ttm) -0.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 2
Last Price $7.62
Previous Close $9.02
Change ($) -1.40
Change (%) -15.52%
Day's Open 8.91
Day's Range 7.60 - 9.18
Day's Volume 4,099,003
52-Week Range 2.16 - 18.80

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 1 day ago

The FDA gave a thumbs-down to CorMedix's antibacterial/anti-fungal catheter lock.

Benzinga - 1 day ago

The FDA has issued a Complete Response Letter for CorMedix Inc's (NASDAQ: CRMD) marketing application seeking approval for DefenCath (taurolidine/heparin catheter lock solution) for catheter-r...

GlobeNewsWire - 1 day ago

BERKELEY HEIGHTS, N.J., March 01, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prev...

GlobeNewsWire - 1 month ago

BERKELEY HEIGHTS, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for th...

Zacks Investment Research - 3 months ago

CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research - 3 months ago

Does CorMedix (CRMD) have what it takes to be a top stock pick for momentum investors? Let's find out.

GlobeNewsWire - 3 months ago

BERKELEY HEIGHTS, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for th...

Seeking Alpha - 3 months ago

Candidate could get approval. But IP not very strong.

Seeking Alpha - 3 months ago

CorMedix Inc. (CRMD) CEO Khoso Baluch on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 3 months ago

CorMedix (CRMD) delivered earnings and revenue surprises of 15.38% and 116.28%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Seeking Alpha - 3 months ago

CorMedix's (CRMD) CEO Khoso Baluch On Q3 2020 Results - Quick Version Earnings Call Transcript

GlobeNewsWire - 4 months ago

Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Seasoned industry veteran with decades of strategic and commercial leaders...

GlobeNewsWire - 4 months ago

BERKELEY HEIGHTS, N.J., Oct. 29, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for th...

GlobeNewsWire - 4 months ago

BERKELEY HEIGHTS, N.J., Oct. 08, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for th...

24/7 Wall Street - 5 months ago

It may be unusual to see nearly a 10% gain from a single analyst call. When analysts call for upside of more than 100% it can attract some attention.

GlobeNewsWire - 5 months ago

Seasoned industry veteran with decades of strategic and commercial leadership experience in the pharmaceutical sector Seasoned industry veteran with decades of strategic and commercial leaders...

GlobeNewsWire - 5 months ago

BERKELEY HEIGHTS, N.J., Sept. 09, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...

GlobeNewsWire - 6 months ago

BERKELEY HEIGHTS, N.J., Aug. 31, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...

Zacks Investment Research - 6 months ago

CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.

Seeking Alpha - 6 months ago

CorMedix's (CRMD) CEO Khoso Baluch on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 6 months ago

CorMedix (CRMD) delivered earnings and revenue surprises of 41.67% and -83.16%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 6 months ago

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time

Benzinga - 6 months ago

Cormedix (AMEX: CRMD) unveils its next round of earnings this Monday, August 10.

GlobeNewsWire - 6 months ago

BERKELEY HEIGHTS, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...

GlobeNewsWire - 7 months ago

BERKELEY HEIGHTS, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD) (the “Company”), a biopharmaceutical company focused on developing and commercializing therapeut...

Zacks Investment Research - 7 months ago

CorMedix (CRMD) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

GlobeNewsWire - 7 months ago

Priority Review of NDA Requested Priority Review of NDA Requested

Zacks Investment Research - 9 months ago

CorMedix (CRMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Seeking Alpha - 9 months ago

CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 9 months ago

CorMedix (CRMD) delivered earnings and revenue surprises of 8.70% and -48.97%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 9 months ago

BERKELEY HEIGHTS, N.J., May 11, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American:  CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...

GlobeNewsWire - 10 months ago

BERKELEY HEIGHTS, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...

Zacks Investment Research - 10 months ago

Top Ranked Momentum Stocks to Buy for April 22nd

Other stocks mentioned: ASC, FUV, OVID
GlobeNewsWire - 10 months ago

BERKELEY HEIGHTS, N.J., April 22, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...

Zacks Investment Research - 10 months ago

As of late, it has definitely been a great time to be an investor CorMedix

Seeking Alpha - 11 months ago

CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 11 months ago

CorMedix (CRMD) delivered earnings and revenue surprises of 12.50% and -73.68%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 11 months ago

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...

GlobeNewsWire - 1 year ago

BERKELEY HEIGHTS, N.J., Feb. 03, 2020 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...

Seeking Alpha - 1 year ago

CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q3 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

CorMedix (CRMD) delivered earnings and revenue surprises of 12.00% and -68.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 1 year ago

Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time

Zacks Investment Research - 1 year ago

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 1 year ago

BERKELEY HEIGHTS, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for ...

GlobeNewsWire - 1 year ago

Pre-NDA Meeting Scheduled Pre-NDA Meeting Scheduled

GlobeNewsWire - 1 year ago

BERKELEY HEIGHTS, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...

GlobeNewsWire - 1 year ago

BERKELEY HEIGHTS, N.J., Sept. 26, 2019 (GLOBE NEWSWIRE) -- CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for...

Seeking Alpha - 1 year ago

CorMedix, Inc. (CRMD) CEO Khoso Baluch on Q2 2019 Results - Earnings Call Transcript

Zacks Investment Research - 1 year ago

CorMedix (CRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About CRMD

CorMedix, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, critical/intensive care, and oncology. The company was... [Read more...]

Industry
Biotechnology
IPO Date
Mar 25, 2010
CEO
Khoso Baluch
Employees
30
Stock Exchange
NASDAQ
Ticker Symbol
CRMD
Full Company Profile

Financial Performance

In 2019, CorMedix's revenue was $283,266, a decrease of -34.09% compared to the previous year's $429,797. Losses were -$16.43 million, -38.75% less than in 2018.

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for CorMedix stock is "Buy." The 12-month stock price forecast is 25.60, which is an increase of 235.96% from the latest price.

Price Target
$25.60
(235.96% upside)
Analyst Consensus: Buy